{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:18:56Z","timestamp":1790853536645,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosci. Bull."],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12264-024-01322-y","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T15:01:06Z","timestamp":1734015666000},"page":"569-582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Dysregulation of Iron Homeostasis Mediated by FTH Increases Ferroptosis Sensitivity in TP53-Mutant Glioblastoma"],"prefix":"10.1007","volume":"41","author":[{"given":"Xuejie","family":"Huan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaobin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Lun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9716-4698","authenticated-orcid":false,"given":"Qian","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1524-7519","authenticated-orcid":false,"given":"Hong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"1322_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019. Neuro Oncol 2022, 24: v1\u2013v95.","journal-title":"Neuro Oncol"},{"key":"1322_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3322\/caac.21613","volume":"70","author":"AC Tan","year":"2020","unstructured":"Tan AC, Ashley DM, L\u00f3pez GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: State of the art and future directions. CA Cancer J Clin 2020, 70: 299\u2013312.","journal-title":"CA Cancer J Clin"},{"key":"1322_CR3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352: 987\u2013996.","journal-title":"N Engl J Med"},{"key":"1322_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10: 459\u2013466.","journal-title":"Lancet Oncol"},{"key":"1322_CR5","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","volume":"20","author":"QT Ostrom","year":"2018","unstructured":"Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2011\u20132015. Neuro Oncol 2018, 20: iv1\u2013iv86.","journal-title":"Neuro Oncol"},{"key":"1322_CR6","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1001\/jamaoncol.2018.1789","volume":"4","author":"QT Ostrom","year":"2018","unstructured":"Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol 2018, 4: 1254\u20131262.","journal-title":"JAMA Oncol"},{"key":"1322_CR7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol 2016, 131: 803\u2013820.","journal-title":"Acta Neuropathol"},{"key":"1322_CR8","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary. Neuro-oncology 2021, 23: 1231\u20131251.","journal-title":"Neuro-oncology"},{"key":"1322_CR9","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","volume":"372","author":"JE Eckel-Passow","year":"2015","unstructured":"Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015, 372: 2499\u20132508.","journal-title":"N Engl J Med"},{"key":"1322_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/neuonc\/not159","volume":"16","author":"J Beiko","year":"2014","unstructured":"Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-oncology 2014, 16: 81\u201391.","journal-title":"Neuro-oncology"},{"key":"1322_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s12264-021-00791-9","volume":"38","author":"Y Huang","year":"2022","unstructured":"Huang Y, Wang Y, Huang Z. A specific peptide vaccine against IDH1(R132H) glioma. Neurosci Bull 2022, 38: 223\u2013225.","journal-title":"Neurosci Bull"},{"key":"1322_CR12","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-12-3002","volume":"19","author":"H Ohgaki","year":"2013","unstructured":"Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res 2013, 19: 764\u2013772.","journal-title":"Clin Cancer Res"},{"key":"1322_CR13","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","volume":"321","author":"DW Parsons","year":"2008","unstructured":"Parsons DW, Jones S, Zhang X, Lin JCH, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321: 1807\u20131812.","journal-title":"Science"},{"key":"1322_CR14","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1093\/neuonc\/noac113","volume":"24","author":"JB Iorgulescu","year":"2022","unstructured":"Iorgulescu JB, Sun C, Neff C, Cioffi G, Gutierrez C, Kruchko C, et al. Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. Neuro-oncology 2022, 24: 1989\u20132000.","journal-title":"Neuro-oncology"},{"key":"1322_CR15","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","volume":"20","author":"AJ Levine","year":"2020","unstructured":"Levine AJ. p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer 2020, 20: 471\u2013480.","journal-title":"Nat Rev Cancer"},{"key":"1322_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/358015a0","volume":"358","author":"DP Lane","year":"1992","unstructured":"Lane DP. p53, guardian of the genome. Nature 1992, 358: 15\u201316.","journal-title":"Nature"},{"key":"1322_CR17","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jmcb\/mjz060","volume":"11","author":"Y Liu","year":"2019","unstructured":"Liu Y, Tavana O, Gu W. p53 modifications: Exquisite decorations of the powerful guardian. J Mol Cell Biol 2019, 11: 564\u2013577.","journal-title":"J Mol Cell Biol"},{"key":"1322_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14344","volume":"520","author":"L Jiang","year":"2015","unstructured":"Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 2015, 520: 57\u201362.","journal-title":"Nature"},{"key":"1322_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/35106009","volume":"1","author":"T Soussi","year":"2001","unstructured":"Soussi T, B\u00e9roud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001, 1: 233\u2013240.","journal-title":"Nat Rev Cancer"},{"key":"1322_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/cdd.2017.185","volume":"25","author":"MP Kim","year":"2018","unstructured":"Kim MP, Lozano G. Mutant p53 partners in crime. Cell Death Differ 2018, 25: 161\u2013168.","journal-title":"Cell Death Differ"},{"key":"1322_CR21","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1016\/j.celrep.2019.08.061","volume":"28","author":"LA Donehower","year":"2019","unstructured":"Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, et al. Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas. Cell Rep 2019, 28: 3010.","journal-title":"Cell Rep"},{"key":"1322_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc.2017.109","volume":"18","author":"VJN Bykov","year":"2018","unstructured":"Bykov VJN, Eriksson SE, Bianchi, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer 2018, 18: 89\u2013102.","journal-title":"Nat Rev Cancer"},{"key":"1322_CR23","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1101\/gad.347542.120","volume":"35","author":"S Pilley","year":"2021","unstructured":"Pilley S, Rodriguez TA, Vousden KH. Mutant p53 in cell-cell interactions. Genes Dev 2021, 35: 433\u2013448.","journal-title":"Genes Dev"},{"key":"1322_CR24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00401-012-1031-3","volume":"124","author":"XY Liu","year":"2012","unstructured":"Liu XY, Gerges N, Korshunov A, Sabha N, Khuong-Quang DA, Fontebasso AM, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1\/IDH2 and TP53 mutations. Acta Neuropathol 2012, 124: 615\u2013625.","journal-title":"Acta Neuropathol"},{"key":"1322_CR25","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1215\/15228517-2009-025","volume":"11","author":"K Ichimura","year":"2009","unstructured":"Ichimura K, Pearson DM, Kocialkowski S, B\u00e4cklund LM, Chan R, Jones DTW, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-oncology 2009, 11: 341\u2013347.","journal-title":"Neuro-oncology"},{"key":"1322_CR26","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell 2013, 155: 462\u2013477.","journal-title":"Cell"},{"key":"1322_CR27","doi-asserted-by":"publisher","first-page":"8424","DOI":"10.1073\/pnas.1431692100","volume":"100","author":"S Kato","year":"2003","unstructured":"Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003, 100: 8424\u20138429.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1322_CR28","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/sj.onc.1201459","volume":"15","author":"CA Midgley","year":"1997","unstructured":"Midgley CA, Lane DP. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 1997, 15: 1179\u20131189.","journal-title":"Oncogene"},{"key":"1322_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051426","volume":"7","author":"M Wiech","year":"2012","unstructured":"Wiech M, Olszewski MB, Tracz-Gaszewska Z, Wawrzynow B, Zylicz M, Zylicz A. Molecular mechanism of mutant p53 stabilization: The role of HSP70 and MDM2. PLoS One 2012, 7: e51426.","journal-title":"PLoS One"},{"key":"1322_CR30","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/jmcb\/mjz067","volume":"11","author":"J Bargonetti","year":"2019","unstructured":"Bargonetti J, Prives C. Gain-of-function mutant p53: History and speculation. J Mol Cell Biol 2019, 11: 605\u2013609.","journal-title":"J Mol Cell Biol"},{"key":"1322_CR31","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41588-018-0204-y","volume":"50","author":"AO Giacomelli","year":"2018","unstructured":"Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet 2018, 50: 1381\u20131387.","journal-title":"Nat Genet"},{"key":"1322_CR32","doi-asserted-by":"publisher","first-page":"6788","DOI":"10.1158\/1078-0432.CCR-19-0126","volume":"25","author":"C Werbrouck","year":"2019","unstructured":"Werbrouck C, Evangelista CCS, Lob\u00f3n-Iglesias MJ, Barret E, Le Teuff G, Merlevede J, et al. TP53 pathway alterations drive radioresistance in diffuse intrinsic pontine gliomas (DIPG). Clin Cancer Res 2019, 25: 6788\u20136800.","journal-title":"Clin Cancer Res"},{"key":"1322_CR33","doi-asserted-by":"publisher","first-page":"33911","DOI":"10.1074\/jbc.M806432200","volume":"283","author":"F Zhang","year":"2008","unstructured":"Zhang F, Wang W, Tsuji Y, Torti SV, Torti FM. Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest. J Biol Chem 2008, 283: 33911\u201333918.","journal-title":"J Biol Chem"},{"key":"1322_CR34","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.3390\/nu11092144","volume":"11","author":"SL Clarke","year":"2019","unstructured":"Clarke SL, Thompson LR, Dandekar E, Srinivasan A, Montgomery MR. Distinct TP53 mutation subtypes differentially influence cellular iron metabolism. Nutrients 2019, 11: 2144.","journal-title":"Nutrients"},{"key":"1322_CR35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1476-4598-7-66","volume":"7","author":"E Morandi","year":"2008","unstructured":"Morandi E, Severini C, Quercioli D, D\u2019Ario G, Perdichizzi S, Capri M, et al. Gene expression time-series analysis of camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines. Mol Cancer 2008, 7: 66.","journal-title":"Mol Cancer"},{"key":"1322_CR36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.canlet.2015.02.012","volume":"360","author":"SW Lee","year":"2015","unstructured":"Lee SW, Kim HK, Lee NH, Yi HY, Kim HS, Hong SH, et al. The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells. Cancer Lett 2015, 360: 195\u2013204.","journal-title":"Cancer Lett"},{"key":"1322_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11060-011-0791-2","volume":"107","author":"K Bajbouj","year":"2012","unstructured":"Bajbouj K, Mawrin C, Hartig R, Schulze-Luehrmann J, Wilisch-Neumann A, Roessner A, et al. P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells. J Neurooncol 2012, 107: 503\u2013516.","journal-title":"J Neurooncol"},{"key":"1322_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.phrs.2017.01.014","volume":"119","author":"Z Que","year":"2017","unstructured":"Que Z, Wang P, Hu Y, Xue Y, Liu X, Qu C, et al. Dihydroartemisin inhibits glioma invasiveness via a ROS to P53 to \u03b2-catenin signaling. Pharmacol Res 2017, 119: 72\u201388.","journal-title":"Pharmacol Res"},{"key":"1322_CR39","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1158\/1535-7163.MCT-16-0807","volume":"17","author":"CN Hinrichs","year":"2018","unstructured":"Hinrichs CN, Ingargiola M, K\u00e4ubler T, L\u00f6ck S, Temme A, K\u00f6hn-Luque A, et al. Arginine deprivation therapy: Putative strategy to eradicate glioblastoma cells by radiosensitization. Mol Cancer Ther 2018, 17: 393\u2013406.","journal-title":"Mol Cancer Ther"},{"key":"1322_CR40","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00394-011-0241-0","volume":"51","author":"A Sielicka-Dudzin","year":"2012","unstructured":"Sielicka-Dudzin A, Borkowska A, Herman-Antosiewicz A, Wozniak M, Jozwik A, Fedeli D, et al. Impact of JNK1, JNK2, and ligase Itch on reactive oxygen species formation and survival of prostate cancer cells treated with diallyl trisulfide. Eur J Nutr 2012, 51: 573\u2013581.","journal-title":"Eur J Nutr"},{"key":"1322_CR41","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s10753-021-01603-y","volume":"45","author":"S He","year":"2022","unstructured":"He S, Xue J, Cao P, Hou J, Cui Y, Chang J, et al. JNK\/itch axis mediates the lipopolysaccharide-induced ubiquitin-proteasome-dependent degradation of ferritin light chain in murine macrophage cells. Inflammation 2022, 45: 1089\u20131100.","journal-title":"Inflammation"},{"key":"1322_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.792293","volume":"12","author":"Q Li","year":"2022","unstructured":"Li Q, Wang M, Zeng L, Guo W, Xu Y, Li C, et al. Deletion of wild-type p53 facilitates bone metastatic function by blocking the AIP4 mediated ligand-induced degradation of CXCR4. Front Pharmacol 2022, 12: 792293.","journal-title":"Front Pharmacol"},{"key":"1322_CR43","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/s41419-019-2064-5","volume":"10","author":"E Park","year":"2019","unstructured":"Park E, Chung SW. ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation. Cell Death Dis 2019, 10: 822.","journal-title":"Cell Death Dis"},{"key":"1322_CR44","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1093\/humrep\/deaa363","volume":"36","author":"Y Li","year":"2021","unstructured":"Li Y, Zeng X, Lu D, Yin M, Shan M, Gao Y. Erastin induces ferroptosis via ferroportin-mediated iron accumulation in endometriosis. Hum Reprod 2021, 36: 951\u2013964.","journal-title":"Hum Reprod"},{"key":"1322_CR45","doi-asserted-by":"publisher","first-page":"16497","DOI":"10.1038\/srep16497","volume":"5","author":"Y Funauchi","year":"2015","unstructured":"Funauchi Y, Tanikawa C, Yi Lo PH, Mori J, Daigo Y, Takano A, et al. Regulation of iron homeostasis by the p53-ISCU pathway. Sci Rep 2015, 5: 16497.","journal-title":"Sci Rep"},{"key":"1322_CR46","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.joca.2020.06.005","volume":"28","author":"LH Burton","year":"2020","unstructured":"Burton LH, Radakovich LB, Marolf AJ, Santangelo KS. Systemic iron overload exacerbates osteoarthritis in the strain 13 guinea pig. Osteoarthritis Cartilage 2020, 28: 1265\u20131275.","journal-title":"Osteoarthritis Cartilage"},{"key":"1322_CR47","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/biof.1520","volume":"45","author":"M Sim\u00e3o","year":"2019","unstructured":"Sim\u00e3o M, Gavaia PJ, Camacho A, Porto G, Pinto IJ, Ea HK, et al. Intracellular iron uptake is favored in Hfe-KO mouse primary chondrocytes mimicking an osteoarthritis-related phenotype. BioFactors 2019, 45: 583\u2013597.","journal-title":"BioFactors"},{"key":"1322_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.821014","volume":"10","author":"A Karim","year":"2022","unstructured":"Karim A, Bajbouj K, Shafarin J, Qaisar R, Hall AC, Hamad M. Iron overload induces oxidative stress, cell cycle arrest and apoptosis in chondrocytes. Front Cell Dev Biol 2022, 10: 821014.","journal-title":"Front Cell Dev Biol"},{"key":"1322_CR49","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s12035-014-8847-x","volume":"52","author":"F Du","year":"2015","unstructured":"Du F, Qian ZM, Luo Q, Yung WH, Ke Y. Hepcidin suppresses brain iron accumulation by downregulating iron transport proteins in iron-overloaded rats. Mol Neurobiol 2015, 52: 101\u2013114.","journal-title":"Mol Neurobiol"},{"key":"1322_CR50","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0092-8674(04)00343-5","volume":"117","author":"MW Hentze","year":"2004","unstructured":"Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: Molecular control of mammalian iron metabolism. Cell 2004, 117: 285\u2013297.","journal-title":"Cell"},{"key":"1322_CR51","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.bbamcr.2012.05.010","volume":"1823","author":"CP Anderson","year":"2012","unstructured":"Anderson CP, Shen M, Eisenstein RS, Leibold EA. Mammalian iron metabolism and its control by iron regulatory proteins. Biochim Biophys Acta 2012, 1823: 1468\u20131483.","journal-title":"Biochim Biophys Acta"},{"key":"1322_CR52","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.7150\/ijms.54860","volume":"18","author":"W Wu","year":"2021","unstructured":"Wu W, Geng Z, Bai H, Liu T, Zhang B. Ammonium Ferric Citrate induced Ferroptosis in Non-Small-Cell Lung Carcinoma through the inhibition of GPX4-GSS\/GSR-GGT axis activity. Int J Med Sci 2021, 18: 1899\u20131909.","journal-title":"Int J Med Sci"},{"key":"1322_CR53","doi-asserted-by":"publisher","first-page":"9547127","DOI":"10.1155\/2020\/9547127","volume":"2020","author":"N Tao","year":"2020","unstructured":"Tao N, Li K, Liu J. Molecular mechanisms of ferroptosis and its role in pulmonary disease. Oxid Med Cell Longev 2020, 2020: 9547127.","journal-title":"Oxid Med Cell Longev"},{"key":"1322_CR54","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 2012, 149: 1060\u20131072.","journal-title":"Cell"},{"key":"1322_CR55","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.molcel.2015.06.011","volume":"59","author":"M Gao","year":"2015","unstructured":"Gao M, Monian P, Quadri N, Ramasamy R, Jiang X. Glutaminolysis and transferrin regulate ferroptosis. Mol Cell 2015, 59: 298\u2013308.","journal-title":"Mol Cell"},{"key":"1322_CR56","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1042\/bj3560311","volume":"356","author":"O Kakhlon","year":"2001","unstructured":"Kakhlon O, Gruenbaum Y, Cabantchik ZI. Repression of the heavy ferritin chain increases the labile iron pool of human K562 cells. Biochem J 2001, 356: 311\u2013316.","journal-title":"Biochem J"},{"key":"1322_CR57","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1146\/annurev-cancerbio-030518-055844","volume":"3","author":"SJ Dixon","year":"2019","unstructured":"Dixon SJ, Stockwell BR. The hallmarks of ferroptosis. Annu Rev Cancer Biol 2019, 3: 35\u201354.","journal-title":"Annu Rev Cancer Biol"}],"container-title":["Neuroscience Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12264-024-01322-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12264-024-01322-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12264-024-01322-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T17:03:23Z","timestamp":1744218203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12264-024-01322-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1322"],"URL":"https:\/\/doi.org\/10.1007\/s12264-024-01322-y","relation":{},"ISSN":["1673-7067","1995-8218"],"issn-type":[{"value":"1673-7067","type":"print"},{"value":"1995-8218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"assertion":[{"value":"3 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there are no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}